Another study explored the potential role of CD90 as a marker for cancer stem cells in gliomas and immunofluorescence staining for CD90 and CD133 in 15 GBM tissues revealed that CD133(+) cancer stem cells are a subpopulation of CD90(+) cells in GBM in vivo. The gene discussed is THY1; the disease is central nervous system cancer.